- Thyroid
- 99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
-
Luca Giovanella, Gaetano Paone, Teresa Ruberto, Luca Ceriani, Pierpaolo Trimboli
-
Endocrinol Metab. 2019;34(1):63-69. Published online February 15, 2019
-
DOI: https://doi.org/10.3803/EnM.2019.34.1.63
-
-
4,903
View
-
75
Download
-
7
Web of Science
-
8
Crossref
-
Abstract
PDFPubReader ePub
- Background
Postoperative routine radioiodine (RAI) treatment is currently debated for patients with low-risk differentiated thyroid carcinoma (DTC) patients. If performed, a low 131I activity (i.e., 1 to 2 GBq) is recommended with the aim to ablate thyroid remnant and facilitate subsequent follow-up by thyroglobulin measurement. The purpose of this study was to evaluate the relationship between postsurgical technetium-99m (99mTc)-pertechnetate scintigraphy and the rate of successful remnant ablation after low activity radioiodine ablation in patients with DTC. MethodsEnrolled were 193 patients with low risk DTC who underwent total thyroidectomy and RAI ablation with a fixed 1.1 GBq activity of 131I. 99mTc-pertechnetate scans were done and thyrotropin stimulated thyroglobulin (sTg) levels measured just before ablation. Ablation effectiveness was assessed 6 to 12 months later by sTg measurement, neck ultrasound and diagnostic whole body scan. ResultsA negative 99mTc-perthecnetate scans was the best predictor of successful ablation (P<0.001) followed by preablative sTg levels <0.8 ng/mL (P=0.008) and 99mTc-pertechnetate uptake rate values <0.9% (P=0.065). Neither sex nor age of the patient at the time of ablation or tumor histology and size showed a significant association with the rate of successful ablation. ConclusionThe 99mTc-pertechnetate scintigraphy is a simple and feasible tool to predict effectiveness of low activity 131I thyroid to ablate thyroid remnants in patients with DTC.
-
Citations
Citations to this article as recorded by
- Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients
Maythinee Chantadisai, Jirarot Wongwijitsook, Napat Ritlumlert, Yothin Rakvongthai Scientific Reports.2024;[Epub] CrossRef - Unexpected 99mTc-pertechnetate avidity of lymph node metastases redicts better response to radioiodine therapy in differentiated hyroid cancer patients with lymph node metastases
Jie Liu American Journal of Nuclear Medicine and Molecular Imaging.2024; 14(1): 63. CrossRef - Sufficiency of a Single Negative Thyroglobulin Standard for Judging the
Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid
Cancer: A Retrospective Study
Yahong Long, Jianhua Jin, Wanchun Zhang Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(10): 1204. CrossRef - Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning
Ogün Bülbül, Demet Nak Acta Otorhinolaryngologica Italica.2024; 44(4): 261. CrossRef - The prognostic value of post thyroidectomy Tc-99m pertechnetate thyroid scan in patients with differentiated thyroid cancer
L.M. Eloteify, Samy M. Algizawy, Aya K.M. Abdelnaim, Nesreen Mekkawy Nuclear Medicine Communications.2023; 44(1): 38. CrossRef - Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer
Qian Zhang, Weina Xu Nuclear Medicine Communications.2022; 43(10): 1051. CrossRef - Clinical significance of extra-thyroid 99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
Bin Long, Li-Fang Yao, Shou-Cong Chen, Jin Shui, Xue-Mei Ye, He-Qing Yi, Cen Lou Journal of International Medical Research.2021; 49(5): 030006052110126. CrossRef - Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine
Antonio Matrone, Alessio Faranda, Francesco Latrofa, Carla Gambale, Delio Stefani Donati, Eleonora Molinaro, Laura Agate, David Viola, Paolo Piaggi, Liborio Torregrossa, Fulvio Basolo, Rossella Elisei The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): e2845. CrossRef
- Thyroid
- Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
-
Pierpaolo Trimboli, Luca Giovanella
-
Endocrinol Metab. 2018;33(2):204-210. Published online June 21, 2018
-
DOI: https://doi.org/10.3803/EnM.2018.33.2.204
-
-
5,234
View
-
66
Download
-
13
Web of Science
-
14
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Calcitonin measurement is pivotal in the management of medullary thyroid carcinoma (MTC), but several pitfalls can affect its reliability. Other potential markers have been proposed, and procalcitonin (ProCT) has been reported as promising. The present study was undertaken to summarize the published data and provide more robust estimates on the reliability of ProCT as marker in the management of patients with MTC. MethodsThe systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The sources comprised studies published through May 2018. Original articles that reported series of MTC patients undergone ProCT during postoperative follow-up were searched. A random-effects model was used for statistical pooling of the data. The I2 index was used to quantify the consistency among the studies. The Egger test evaluated the possible presence of significant publication bias. Quality assessment of the studies was performed according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). ResultsAccording to inclusion and exclusion criteria five papers, reporting 296 MTC patients undergone ProCT evaluation, were finally selected. The number of MTC with recurrence was 140. The pooled sensitivity of ProCT in detecting recurrence was 96% (95% confidence interval [CI], 92% to 99%), with neither heterogeneity (I2=0%) nor publication bias (Egger test, 3.16; P=0.99). The pooled specificity was 96% (95% CI, 87% to 100%) with mild heterogeneity (I2=66.6%), while Egger test was not calculable. ConclusionThe present meta-analysis provides evidence that ProCT is reliable to manage MTC patients during their postoperative follow-up.
-
Citations
Citations to this article as recorded by
- Insulinoma with Hyperprocalcitoninemia and Hypercalcitoninemia Showing Coexpression of Insulin and Calcitonin in Its Tumor Cells
Tomoko Kaketaka, Ikuo Mineo, Yu Kimura, Naohiko Ito, Yukiyoshi Okauchi, Hiromi Tamura, Shiro Adachi, Hiromi Iwahashi Internal Medicine.2024; 63(10): 1415. CrossRef - Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
Il Youb Jeong, Hyeok Jun Yun, Seok-Mo Kim, Yongjung Park Diagnostics.2024; 14(16): 1809. CrossRef - [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
Luka Lezaic, Paola Anna Erba, Clemens Decristoforo, Katja Zaletel, Renata Mikolajczak, Helmut Maecke, Theodosia Maina, Mark Konijnenberg, Petra Kolenc, Malgorzata Trofimiuk-Müldner, Elwira Przybylik-Mazurek, Irene Virgolini, Marion de Jong, Alide C Fröber European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(3): 892. CrossRef - Diagnostic tests for medullary thyroid carcinoma: an umbrella review
Pierpaolo Trimboli, Caterina Mian, Arnoldo Piccardo, Giorgio Treglia Endocrine.2023; 81(2): 183. CrossRef - Advances in Diagnostics and Therapy of Medullary Thyroid Carcinoma (MTC)– A Mini-Review
Michał Miciak, Krzysztof Jurkiewicz Clinical Cancer Investigation Journal.2023; 12(5): 1. CrossRef - Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19
Aparajita Sen, Arti Nigam, Meenakshi Vachher International Journal of Peptide Research and Therapeutics.2022;[Epub] CrossRef - A pregnancy-specific reference interval for procalcitonin
Samuel Dockree, Jennifer Brook, Tim James, Brian Shine, Manu Vatish Clinica Chimica Acta.2021; 513: 13. CrossRef - Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma
Luca Giovanella, Martina Fontana, Franco Keller, Frederik A. Verburg, Luca Ceriani Clinical Chemistry and Laboratory Medicine (CCLM).2021; 59(4): 743. CrossRef - Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence
Qiaodan Zhu, Dong Xu BMC Cancer.2021;[Epub] CrossRef - Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents
Felix Eckelt, Roland Pfaeffle, Wieland Kiess, Juergen Kratzsch Journal of Pediatric Endocrinology and Metabolism.2021; 34(12): 1491. CrossRef - Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis
Marisa A. Bartz-Kurycki, Omowunmi E. Oluwo, Lilah F. Morris-Wiseman Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110496. CrossRef - Diagnostic Challenges of Medullary Thyroid Carcinoma
Robert D. Leimbach, Thanh D. Hoang, Mohamed K.M. Shakir Oncology.2021; 99(7): 422. CrossRef - The Diagnostic and Antibiotic Reference Values of Procalcitonin for Intracranial Infection After Craniotomy
Lei Zhu, Lun Dong, Yuping Li, Guangyu Lu, Hengzhu Zhang, Xingdong Wang, Xiaoguang Liu, Zhenfei Teng, Boming Xia, Peng Zhang World Neurosurgery.2019; 126: e1. CrossRef - Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee Endocrinology and Metabolism.2018; 33(2): 195. CrossRef
- Thyroid
- The Significance of Having an Excellent Patient's Comfort with Thyroid Core Needle Biopsy
-
Pierpaolo Trimboli, Luca Giovanella
-
Endocrinol Metab. 2018;33(1):53-54. Published online March 21, 2018
-
DOI: https://doi.org/10.3803/EnM.2018.33.1.53
-
-
3,206
View
-
41
Download
-
2
Web of Science
-
2
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
Faridul Haq, Andrey Bychkov, Chan Kwon Jung Endocrine Pathology.2022; 33(4): 472. CrossRef - Does Radiofrequency Ablation Induce Neoplastic Changes in Benign Thyroid Nodules: A Preliminary Study
Su Min Ha, Jun Young Shin, Jung Hwan Baek, Dong Eun Song, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee Endocrinology and Metabolism.2019; 34(2): 169. CrossRef
|